{
    "clinical_study": {
        "@rank": "90620", 
        "arm_group": {
            "arm_group_label": "Ferumoxytol followed by MM-398", 
            "arm_group_type": "Experimental", 
            "description": "Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 80 mg/m2 IV over 90 min on Days 1 and 15 of every 4 weekly cycle"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase I Pilot study to understand the biodistribution of MM-398 and to determine\n      the feasibility of using Ferumoxytol as a tumor imaging agent."
        }, 
        "brief_title": "Pilot Study to Determine Biodistribution of MM-398 and Feasibility of Ferumoxytol as a Tumor Imaging Agent", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Solid Tumors", 
            "Triple Negative Breast Cancer", 
            "Non Small Cell Lung Cancer", 
            "Colorectal Cancer", 
            "ER/PR Positive Breast Cancer", 
            "Pancreatic Cancer", 
            "Ovarian Cancer", 
            "Gastric Cancer", 
            "Gastro-Esophageal Junction Adenocarcinoma", 
            "Head and Neck Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Breast Neoplasms", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Colorectal Neoplasms", 
                "Head and Neck Neoplasms", 
                "Lung Neoplasms", 
                "Stomach Neoplasms", 
                "Ovarian Neoplasms", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically confirmed diagnosis of solid tumors, CRC, TNBC, ER/PR Breast Cancer,\n             NSCLC, Pancreatic Cancer, Ovarian Cancer, Gastric Cancer, GEJ adenocarcinoma, Head\n             and Neck Cancer\n\n          -  Metastatic disease\n\n          -  ECOG Performance Status 0 to 2\n\n          -  Adequate bone marrow, hepatic and renal function\n\n          -  Normal ECG\n\n          -  18 years of age or above\n\n          -  Able to understand and sign informed consent\n\n        Exclusion Criteria:\n\n          -  Active CNS metastasis\n\n          -  Clinically significant GI disorders\n\n          -  Prior irinotecan or bevacizumab therapy within last 6 months\n\n          -  Known hypersensitivity to MM-398 or ferumoxytol\n\n          -  Inability to undergo MRI\n\n          -  Active infection\n\n          -  Pregnant or breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01770353", 
            "org_study_id": "MM-398-01-01-02"
        }, 
        "intervention": {
            "arm_group_label": "Ferumoxytol followed by MM-398", 
            "description": "Ferumoxytol 5 mg/kg IV at 1mL/sec, given once. MM-398 80 mg/m2 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity", 
            "intervention_name": "Ferumoxytol followed by MM-398", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ferumoxytol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "solid tumors", 
            "Triple Negative Breast cancer", 
            "Non Small Cell Lung cancer", 
            "Colorectal Cancer", 
            "MM-398", 
            "nanoliposomal irinotecan", 
            "Ferumoxytol", 
            "ER/PR positive Breast Cancer", 
            "Pancreatic Cancer", 
            "Ovarian Cancer", 
            "Gastric Cancer", 
            "Gastro-Esophageal Junction Adenocarcinoma", 
            "Head and Neck Cancer"
        ], 
        "lastchanged_date": "August 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Scottsdale", 
                    "country": "United States", 
                    "state": "Arizona"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study in Patients Treated With MM-398 to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages", 
        "overall_contact": {
            "email": "ebayever@merrimackpharma.com", 
            "last_name": "Eliel Bayever, MD", 
            "phone": "617-441-1000"
        }, 
        "overall_official": {
            "affiliation": "Merrimack Pharmaceuticals", 
            "last_name": "Eliel Bayever, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Measure tumor levels of irinotecan and SN-38 (in ng/mL)", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01770353"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety profile of MM-398 in the presence of ferumoxytol (number and type of Adverse Events compared with histological control)", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Tumor response Rate measured by RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 guidelines", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "50% of total time of drug in plasma", 
                "measure": "Half-life of the drug (t 1/2) in number of hours", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Maximum concentration of drug in plasma (Cmax) in ng/mL", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Area under the plasma drug concentration versus time curve", 
                "measure": "Measure of drug availability in the plasma (AUC) in ng/mL x hours", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Merrimack Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merrimack Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}